Teva Pharmaceutical Industries (TEVA) Gains from Investment Securities: 2009-2025
Historic Gains from Investment Securities for Teva Pharmaceutical Industries (TEVA) over the last 13 years, with Sep 2025 value amounting to -$2.0 million.
- Teva Pharmaceutical Industries' Gains from Investment Securities was N/A to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $762.0 million, marking a year-over-year change of. This contributed to the annual value of $471.0 million for FY2024, which is 58.05% up from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Gains from Investment Securities stood at -$2.0 million for Q3 2025, which was down 100.42% from $471.0 million recorded in Q4 2024.
- Teva Pharmaceutical Industries' Gains from Investment Securities' 5-year high stood at $547.0 million during Q4 2022, with a 5-year trough of -$3.0 million in Q3 2021.
- Its 3-year average for Gains from Investment Securities is $127.8 million, with a median of $2.5 million in 2023.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 106.67% in 2021, then surged by 133.33% in 2023.
- Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Gains from Investment Securities stood at $498.0 million in 2021, then climbed by 9.84% to $547.0 million in 2022, then plummeted by 46.62% to $292.0 million in 2023, then soared by 61.30% to $471.0 million in 2024, then reached -$2.0 million in 2025.
- Its Gains from Investment Securities stands at -$2.0 million for Q3 2025, versus $471.0 million for Q4 2024 and $292.0 million for Q4 2023.